 |
|
|
| |
The Effect of Renal Impairment on Single-Dose
Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor
|
| |
| |
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 19-21, 2014
Garimella T,1 Wang R,1 Luo W-L,2 Hwang C,1 Sherman D,1 Kandoussi H,2 Marbury T,3 Alcorn H,4 Bertz R,1 Bifano M1
1Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA; 2Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA;
3Orlando Clinical Research Center, Orlando, FL, USA; 4DaVita Clinical Research, Minneapolis, MN, USA
|
| |
|
|
|
|
|
